Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingelise Gordon

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Biorxiv : the Preprint Server for Biology|April 5, 2022
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clonesNoemia S Lima, Maryam Musayev, Timothy S Johnston, et al.
Nature Communications|December 14, 2022
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clonesNoemia S Lima, Maryam Musayev, Timothy S Johnston, et al.
The New England Journal of Medicine|July 30, 2020
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman PrimatesKizzmekia S Corbett, Barbara Flynn, Kathryn E Foulds, et al.
Science (New York, N.Y.)|August 13, 2021
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variantsAmarendra Pegu, Sarah E O'Connell, Stephen D Schmidt, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Nature Medicine|April 12, 2022
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trialJoseph P Casazza, Evan M Cale, Sandeep Narpala, et al.
Biorxiv : the Preprint Server for Biology|April 5, 2022
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clonesNoemia S Lima, Maryam Musayev, Timothy S Johnston, et al.
Nature Communications|December 14, 2022
Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clonesNoemia S Lima, Maryam Musayev, Timothy S Johnston, et al.
The New England Journal of Medicine|July 30, 2020
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman PrimatesKizzmekia S Corbett, Barbara Flynn, Kathryn E Foulds, et al.
Science (New York, N.Y.)|August 13, 2021
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variantsAmarendra Pegu, Sarah E O'Connell, Stephen D Schmidt, et al.
Pageof 2